Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant
There was no significant difference in transplant-related mortality or overall survival.
Diagnosis & Disease Information
Omidubicel May Provide Long-Term Benefits With Allogeneic Transplantation for Hematologic Malignancies
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
Treosulfan Exposure and Transplantation Outcomes With Thalassemia Major
Researchers sought to determine whether there is a link between outcomes of hematopoietic transplantation and treosulfan exposure in high-risk thalassemia major.
Defibrotide Useful in Treating Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome
Researchers sought to determine whether defibrotide would be a useful treatment in patients with veno-occlusive disease/sinusoidal obstruction syndrome
Results Support Allo-HSCT After CAR-T Failure in Large B-Cell Lymphoma
The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.
Real-World Data Confirm Lack of Standard Care for Triple-Exposed Multiple Myeloma
After triple-class exposure, patients received more than 50 unique treatment regimens.
Allo-HSCT May Be Effective for Patients With Hepatosplenic T-Cell Lymphoma
Researchers sought to determine whether allo-HSCT would be helpful in treating patients with hepatosplenic T-cell lymphoma.
Adding Eprenetapopt to Maintenance Azacitidine Promising After HCT in MDS/AML
Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.
Beti-Cel Shows Promise in Patients With Transfusion-Dependent Beta-Thalassemia
Researchers sought to determine whether betibeglogene autotemcel would be safe and effective in patients with transfusion-dependent beta-thalassemia.
High-Dose Granulocyte Colony Stimulating Factor Mobilization Effective in Donors With Sickle Cell Trait
Researchers sought to determine whether high-dose granulocyte colony stimulating factor mobilization would be safe in adult donors with sickle cell disease trait undergoing PBSC collection for stem cell transplantation.
- Loading...
Loading...
Next post in Tandem Meetings 2022
Loading... 
Loading...